Imunon, Inc. (IMNN)

NASDAQ: IMNN · IEX Real-Time Price · USD
1.47
+0.07 (5.00%)
At close: Dec 2, 2022 4:00 PM
1.48
+0.01 (0.68%)
After-hours: Dec 2, 2022 4:00 PM EST
5%
Market Cap 10.41M
Revenue (ttm) 500,000
Net Income (ttm) -26.89M
Shares Out 7.10M
EPS (ttm) -4.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,813
Open 1.38
Previous Close 1.4
Day's Range 1.38 - 1.49
52-Week Range 1.35 - 10.95
Beta 2.09
Analysts Buy
Price Target 23.72 (+1,513.6%)
Earnings Date Nov 14, 2022

About IMNN

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies... [Read more]

Industry Biotechnology
IPO Date Mar 5, 1985
CEO Michael Tardugno
Employees 29
Stock Exchange NASDAQ
Ticker Symbol IMNN
Full Company Profile

Financial Performance

In 2021, Imunon's revenue was $500,000, a change of 0.00% compared to the previous year's $500,000. Losses were -$20.77 million, -3.32% less than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for IMNN stock is "Buy." The 12-month stock price forecast is 23.72, which is an increase of 1,513.61% from the latest price.

Price Target
$23.72
(1,513.61% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Ke...

LAWRENCEVILLE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- I MUNON , Inc.  (NASDAQ: IMNN), a clinical-stage drug development company, announces that Khursheed Anwer, Ph.D., the company's Executive Vice Pres...

2 days ago - GlobeNewsWire

IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – Decemb...

LAWRENCEVILLE, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- I MUNON , Inc.  (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive ...

1 week ago - GlobeNewsWire

IMUNON Announces Strategic Investment in Transomic Technologies

Investment of $375,000 with Senior Convertible Note s and Warrants; Strengthens Development Capabilities for IMUNON 's PLACCINE DNA Vaccine Platform

2 weeks ago - GlobeNewsWire

IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update

Conference Call Today at 11:00 a.m. ET

2 weeks ago - GlobeNewsWire

IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON's PLACCINE Plasmid DN...

Successful combination of technologies will expand the opportunities for I MUNON 's DNA-based modality and broaden application s for the PLACCINE n ucleic a cid v accine p latform as a n alternative to ...

3 weeks ago - GlobeNewsWire

Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022

LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, announce...

3 weeks ago - GlobeNewsWire

Imunon Appoints James E. Dentzer to its Board of Directors

CEO of Curis brings extensive biopharmaceutical financial experience to the Board

2 months ago - GlobeNewsWire

Imunon Reports Partial Results from Ongoing Non-human Primate Study

Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines

2 months ago - GlobeNewsWire

Imunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Imunon , Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today ann...

2 months ago - GlobeNewsWire

IMUNON to Present at Chardan's 6th Annual Genetic Medicines Conference

LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon , Inc.  (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive ...

2 months ago - GlobeNewsWire

Celsion Corporation Announces Company Name Change to Imunon, Inc.

New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines

2 months ago - GlobeNewsWire

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone

2 months ago - GlobeNewsWire

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30...

LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive O...

2 months ago - GlobeNewsWire

Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Execut...

2 months ago - GlobeNewsWire

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model

3 months ago - GlobeNewsWire

Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT

3 months ago - GlobeNewsWire

Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, Augu...

LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announce...

3 months ago - GlobeNewsWire

Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that ...

4 months ago - GlobeNewsWire

Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

Michael H. Tardugno appointed Executive Chairman of the Board

4 months ago - GlobeNewsWire

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Por...

Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit

5 months ago - GlobeNewsWire

Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT

6 months ago - GlobeNewsWire

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies

6 months ago - GlobeNewsWire

Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 1...

LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced...

6 months ago - GlobeNewsWire

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccin...

Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus

7 months ago - GlobeNewsWire

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer ...

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR A nnual M eeti ng

7 months ago - GlobeNewsWire